284 related articles for article (PubMed ID: 32456653)
1. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
Annemans L; Makady A
Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
[TBL] [Abstract][Full Text] [Related]
2. Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases").
Grimm SE; Pouwels X; Ramaekers BLT; Wijnen B; Knies S; Grutters J; Joore MA
Orphanet J Rare Dis; 2021 Feb; 16(1):62. PubMed ID: 33522936
[TBL] [Abstract][Full Text] [Related]
3. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
Fontrier AM
Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
[TBL] [Abstract][Full Text] [Related]
4. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
5. Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
Capkun G; Corry S; Dowling O; Asad Zadeh Vosta Kolaei F; Takyar S; Furtado C; Jónsson P; Kleinermans D; Lambert L; Schiel A; Facey K
Int J Technol Assess Health Care; 2022 Nov; 38(1):e79. PubMed ID: 36321447
[TBL] [Abstract][Full Text] [Related]
6. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?
Menon D; Stafinski T; Dunn A; Short H
Patient; 2015 Feb; 8(1):29-39. PubMed ID: 25516506
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence for coverage determination of treatments for rare diseases.
Dayer VW; Drummond MF; Dabbous O; Toumi M; Neumann P; Tunis S; Teich N; Saleh S; Persson U; von der Schulenburg JG; Malone DC; Salimullah T; Sullivan SD
Orphanet J Rare Dis; 2024 Feb; 19(1):47. PubMed ID: 38326894
[TBL] [Abstract][Full Text] [Related]
8. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
9. Novel approach to decision making for orphan drugs.
Decker B; Mlcoch T; Pustovalova A; Dolezal T
Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
[TBL] [Abstract][Full Text] [Related]
10. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Gutierrez L; Patris J; Hutchings A; Cowell W
Orphanet J Rare Dis; 2015 May; 10():53. PubMed ID: 25935555
[TBL] [Abstract][Full Text] [Related]
11. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
Sievers H; Joos A; Hiligsmann M
Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
[TBL] [Abstract][Full Text] [Related]
13. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties.
Pontes C; Fontanet JM; Vives R; Sancho A; Gómez-Valent M; Ríos J; Morros R; Martinalbo J; Posch M; Koch A; Roes K; Oude Rengerink K; Torrent-Farnell J; Torres F
Orphanet J Rare Dis; 2018 Nov; 13(1):206. PubMed ID: 30442155
[TBL] [Abstract][Full Text] [Related]
14. How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada.
Mills M; Kanavos P
Health Policy; 2022 Nov; 126(11):1130-1143. PubMed ID: 36050193
[TBL] [Abstract][Full Text] [Related]
15. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
16. The impact of rarity in NICE's health technology appraisals.
Clarke S; Ellis M; Brownrigg J
Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
[TBL] [Abstract][Full Text] [Related]
17. Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
Cavaller-Bellaubi M; Hughes-Wilson W; Kubinová Š; Van de Casteele M; Van Lente EJ; Degortes E; Pontén J; Eichler HG; Le Cam Y; Boselli S; Bucsics A
Orphanet J Rare Dis; 2023 Jun; 18(1):144. PubMed ID: 37308991
[TBL] [Abstract][Full Text] [Related]
18. HTA Barriers for Conditional Approval Drugs.
Mills M
Pharmacoeconomics; 2023 May; 41(5):529-545. PubMed ID: 36821044
[TBL] [Abstract][Full Text] [Related]
19. Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries.
Kanavos P; Visintin E; Gentilini A
Soc Sci Med; 2023 Aug; 331():116045. PubMed ID: 37450991
[TBL] [Abstract][Full Text] [Related]
20. How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?
Cowie MR; Bozkurt B; Butler J; Briggs A; Kubin M; Jonas A; Adler AI; Patrick-Lake B; Zannad F
Int J Cardiol; 2022 Oct; 365():61-68. PubMed ID: 35905826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
